TLR4 and acute kidney injury: SAC can be developed as a promising therapeutic agent to provide potent anti-inflammatory and antioxidant effects against cisplatin-associated AKI, mediated by inhibiting the TLR-4-NF-κB–MAPK-, HO-1–Nrf2- and CaMKK–AMPK–Sirt1-associated signaling axes (Figure 10).